Results 161 to 170 of about 34,807 (281)

Update on Selected Adverse Events of Concern Following Immunization With Acellular Pertussis Vaccines, a Narrative Review

Acta Paediatrica, Volume 115, Issue 11, Page 2370-2379, November 2026.
ABSTRACT Aim To provide an update paper on evidence of adverse events of concern following immunization (AEFI) with pertussis vaccines, focusing primarily on acellular (aP) vaccines. Methods Evidence was synthesised from epidemiological studies, systematic reviews over recent decades, expert interpretations in reviews from relevant research teams and ...
Lennart Nilsson, Jann Storsaeter
wiley   +1 more source

Clinical Pharmacogenetics: Results After Implementation of Preemptive Tests in Daily Routine

Background/Objectives: The clinical implementation of pharmacogenetics (PGx) remains limited, even for well-established drug–gene interactions. In addition to insufficient infrastructure and PGx education among healthcare professionals, there is ...
María Teresa Nieto-Sánchez, Alicia Torres-García, Emilio Fernández-Varón, Isabel Blancas, Rocío Morón, Xando Díaz-Villamarín, José Cabeza-Barrera, María Martínez-Pérez   +7 more
core   +1 more source

Serum Concentration Relationships of Candesartan in Migraine Prevention

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 5, November 2026.
ABSTRACT Migraine is a common disabling disorder, and optimising affordable preventive treatments remains highly relevant. Candesartan is an effective and well‐tolerated preventive treatment, but little is known about its dose‐concentration–response relationships.
Hedda Skogum Riise, Melanie Simpson, Ketil Arne Espnes, Erling Andreas Tronvik, Andreas Kattem Husøy, Lise R. Øie, Anker Stubberud, Emil Kofoed, Aurora Harsvik Alstad, Hedda Hoff Hagen, Maren Guldteig Lien, Marie Larsen Stavseng, Ella Rian Sæther, Tore Wergeland   +13 more
wiley   +1 more source

Repositioning candidate gene approaches in the post-GWAS era: a clinical perspective from psychiatric pharmacogenetics. [PDF]

Front Genet
Pjevac M, Bon J, Dolžan V.
europepmc   +1 more source

Comparison of pharmacogenomic guidance in Australian prescribing resources and international pharmacogenomic guidelines. [PDF]

Intern Med J
Abstract Background Pharmacogenomic‐guided medication management optimises drug therapy to enhance patient outcomes. Despite clinical utility, implementation in Australia remains limited, partly due to the lack of clear and consistent guidance. Aim This study evaluated the presence and consistency of pharmacogenomic testing indication categories and ...
Soueid R, Thomas JLA, Hesson LB, Hughes S, Stocker SL.   +4 more
europepmc   +2 more sources

Stereoselective Determination of Omeprazole and 5‐Hydroxy‐Omeprazole in Dried Blood Spots for CYP2C19 Activity Assessment

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 5, November 2026.
ABSTRACT We previously proposed stereoselective 5‐hydroxy‐omeprazole/omeprazole cut‐offs for R‐ and S‐omeprazole to differentiate between rapid, normal, and poor CYP2C19 metabolisers. However, the performance of these stereoselective CYP2C19 phenotyping approaches has never been compared with conventional racemic omeprazole phenotyping.
Toon Hectors, Kenza Abouir, Emmanuel Varesio, Martijn L. Manson, Youssef Daali, Caroline Samer   +5 more
wiley   +1 more source

Editorial: Pharmacogenetics and pharmacogenomics in psychiatry: challenges and opportunities. [PDF]

Front Pharmacol
Samardzic J, Allegaert K, Karamperis K.
europepmc   +1 more source

A Phase 1 Study of MK‐1942, a Negative Allosteric Modulator of mGluR2, in Healthy Japanese to Flexibly Assess Factors Including CYP2C19 Phenotype

Clinical and Translational Science, Volume 19, Issue 11, November 2026.
ABSTRACT MK‐1942 is a negative allosteric modulator of the metabotropic glutamate receptor 2 that was investigated for the treatment of Alzheimer's disease and depression. Nonclinical studies with recombinant human CYPs and genotyped human hepatocytes suggested that CYP2C19 is involved in the metabolism of MK‐1942. Given the high incidence of different
Chihiro Hasegawa, Yohei Doi, Tomona Hirano, Masayoshi Shirakawa, Saori Tsuchiya, Hiroyuki Yoshitsugu, Kenichi Furihata, Callie Miller, Sonal Singh, Tamara Cabalu, Ka Lai Yee, Tjerk Bueters, Zoi Alexopoulou   +12 more
wiley   +1 more source

Editorial: Use of bioinformatics in pharmacogenetics to optimize drug efficacy. [PDF]

Front Pharmacol
Jaafari A, Tilaoui M.
europepmc   +1 more source

Genetic and Clinical Determinants of Variation in Drug Response in Type 2 Diabetes: Insights From the Scottish and UK Biobank Cohorts

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10780-10794, November 2026.
ABSTRACT Objective Treatment response in type 2 diabetes (T2D) varies widely among individuals. This study aimed to quantify the contributions of clinical characteristics and genetic predisposition as measured through partitioned polygenic risk scores (pPRS) to variation in glycemic response to glucose‐lowering therapies.
S. Garg, R. Kitchen, R. Gupta, L. Donnelly, E. R. Pearson   +4 more
wiley   +1 more source